vs
Amprius Technologies, Inc.（AMPX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Amprius Technologies, Inc.的1.2倍（$30.3M vs $25.2M），Amprius Technologies, Inc.净利率更高（-96.7% vs -221.3%，领先124.7%），Amprius Technologies, Inc.同比增速更快（137.4% vs 43.0%），Amprius Technologies, Inc.自由现金流更多（$-5.9M vs $-52.8M），过去两年Amprius Technologies, Inc.的营收复合增速更高（228.7% vs 39.4%）
Amprius Technologies是一家先进储能技术企业，主打自研硅负极技术的高能量密度锂离子电池，产品覆盖航空航天、国防、电动出行、便携式电子设备等领域，可提供续航更长、充电速度更快的电池解决方案。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
AMPX vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$25.2M
营收增速更快
AMPX
高出94.4%
43.0%
净利率更高
AMPX
高出124.7%
-221.3%
自由现金流更多
AMPX
多$46.9M
$-52.8M
两年增速更快
AMPX
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.2M | $30.3M |
| 净利润 | $-24.4M | $-67.1M |
| 毛利率 | 23.6% | — |
| 营业利润率 | -100.9% | -190.0% |
| 净利率 | -96.7% | -221.3% |
| 营收同比 | 137.4% | 43.0% |
| 净利润同比 | -113.6% | -31.2% |
| 每股收益（稀释后） | $-0.19 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPXRGNX
| Q4 25 | $25.2M | $30.3M | ||
| Q3 25 | $21.4M | $29.7M | ||
| Q2 25 | $15.1M | $21.4M | ||
| Q1 25 | $11.3M | $89.0M | ||
| Q4 24 | $10.6M | $21.2M | ||
| Q3 24 | $7.9M | $24.2M | ||
| Q2 24 | $3.3M | $22.3M | ||
| Q1 24 | $2.3M | $15.6M |
净利润AMPXRGNX
| Q4 25 | $-24.4M | $-67.1M | ||
| Q3 25 | $-3.9M | $-61.9M | ||
| Q2 25 | $-6.4M | $-70.9M | ||
| Q1 25 | $-9.4M | $6.1M | ||
| Q4 24 | $-11.4M | $-51.2M | ||
| Q3 24 | $-10.8M | $-59.6M | ||
| Q2 24 | $-12.5M | $-53.0M | ||
| Q1 24 | $-9.9M | $-63.3M |
毛利率AMPXRGNX
| Q4 25 | 23.6% | — | ||
| Q3 25 | 15.5% | — | ||
| Q2 25 | 8.9% | — | ||
| Q1 25 | -20.9% | — | ||
| Q4 24 | -21.2% | 70.2% | ||
| Q3 24 | -64.9% | 48.8% | ||
| Q2 24 | -195.2% | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率AMPXRGNX
| Q4 25 | -100.9% | -190.0% | ||
| Q3 25 | -21.9% | -176.3% | ||
| Q2 25 | -45.2% | -296.3% | ||
| Q1 25 | -85.7% | 13.6% | ||
| Q4 24 | -110.6% | -242.1% | ||
| Q3 24 | -143.3% | -256.6% | ||
| Q2 24 | -386.6% | -251.3% | ||
| Q1 24 | -441.7% | -408.8% |
净利率AMPXRGNX
| Q4 25 | -96.7% | -221.3% | ||
| Q3 25 | -18.2% | -208.3% | ||
| Q2 25 | -42.3% | -331.8% | ||
| Q1 25 | -83.0% | 6.8% | ||
| Q4 24 | -107.4% | -241.3% | ||
| Q3 24 | -138.1% | -246.3% | ||
| Q2 24 | -374.2% | -237.7% | ||
| Q1 24 | -423.2% | -405.4% |
每股收益（稀释后）AMPXRGNX
| Q4 25 | $-0.19 | $-1.30 | ||
| Q3 25 | $-0.03 | $-1.20 | ||
| Q2 25 | $-0.05 | $-1.38 | ||
| Q1 25 | $-0.08 | $0.12 | ||
| Q4 24 | $-0.11 | $-0.99 | ||
| Q3 24 | $-0.10 | $-1.17 | ||
| Q2 24 | $-0.13 | $-1.05 | ||
| Q1 24 | $-0.11 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $103.8M | $102.7M |
| 总资产 | $156.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMPXRGNX
| Q4 25 | $90.5M | $230.1M | ||
| Q3 25 | $73.2M | $274.2M | ||
| Q2 25 | $54.2M | $323.3M | ||
| Q1 25 | $48.4M | $267.9M | ||
| Q4 24 | $55.2M | $234.7M | ||
| Q3 24 | $35.0M | $255.5M | ||
| Q2 24 | $46.4M | $290.4M | ||
| Q1 24 | $39.0M | $338.7M |
股东权益AMPXRGNX
| Q4 25 | $103.8M | $102.7M | ||
| Q3 25 | $103.2M | $161.5M | ||
| Q2 25 | $76.7M | $213.7M | ||
| Q1 25 | $70.4M | $274.2M | ||
| Q4 24 | $69.5M | $259.7M | ||
| Q3 24 | $56.0M | $301.4M | ||
| Q2 24 | $65.1M | $348.3M | ||
| Q1 24 | $59.9M | $390.7M |
总资产AMPXRGNX
| Q4 25 | $156.9M | $453.0M | ||
| Q3 25 | $156.5M | $525.2M | ||
| Q2 25 | $123.0M | $581.0M | ||
| Q1 25 | $118.5M | $490.9M | ||
| Q4 24 | $121.1M | $466.0M | ||
| Q3 24 | $104.2M | $519.1M | ||
| Q2 24 | $112.8M | $569.4M | ||
| Q1 24 | $104.7M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | -23.2% | -174.0% |
| 资本支出强度资本支出/营收 | 9.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-35.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流AMPXRGNX
| Q4 25 | $-3.5M | $-52.3M | ||
| Q3 25 | $-9.2M | $-56.0M | ||
| Q2 25 | $-4.3M | $-49.3M | ||
| Q1 25 | $-14.1M | $33.6M | ||
| Q4 24 | $-6.1M | $-31.6M | ||
| Q3 24 | $-9.5M | $-40.5M | ||
| Q2 24 | $-8.0M | $-45.5M | ||
| Q1 24 | $-9.8M | $-55.5M |
自由现金流AMPXRGNX
| Q4 25 | $-5.9M | $-52.8M | ||
| Q3 25 | $-9.7M | $-56.5M | ||
| Q2 25 | $-5.0M | $-49.7M | ||
| Q1 25 | $-15.0M | $32.6M | ||
| Q4 24 | $-9.7M | $-32.7M | ||
| Q3 24 | $-10.9M | $-40.9M | ||
| Q2 24 | $-9.6M | $-46.0M | ||
| Q1 24 | $-13.7M | $-56.0M |
自由现金流率AMPXRGNX
| Q4 25 | -23.2% | -174.0% | ||
| Q3 25 | -45.1% | -189.9% | ||
| Q2 25 | -33.1% | -232.8% | ||
| Q1 25 | -133.3% | 36.6% | ||
| Q4 24 | -91.4% | -154.2% | ||
| Q3 24 | -138.3% | -168.9% | ||
| Q2 24 | -285.9% | -206.2% | ||
| Q1 24 | -585.4% | -358.5% |
资本支出强度AMPXRGNX
| Q4 25 | 9.3% | 1.7% | ||
| Q3 25 | 1.9% | 1.7% | ||
| Q2 25 | 4.8% | 1.8% | ||
| Q1 25 | 8.1% | 1.2% | ||
| Q4 24 | 34.1% | 5.1% | ||
| Q3 24 | 17.0% | 1.3% | ||
| Q2 24 | 48.0% | 2.1% | ||
| Q1 24 | 166.8% | 3.6% |
现金转化率AMPXRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPX
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
